At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the November 2026 edition.
The IMF team of medical editors has provided overviews of key studies. We encourage you to visit the original journal articles for full details and to deepen your understanding. Check the IMF Newsroom monthly for updates like this one.
In the Journals (Key Myeloma Research in November 2026)
"Multiplex immunohistochemistry in multiple myeloma: principles, spatial profiling applications, and emerging frontiers in immunooncology."
Source
Zhou D, Guo X, Wang C and Bi L (2026) Multiplex immunohistochemistry in multiple myeloma: principles, spatial profiling applications, and emerging frontiers in immunooncology. Front. Oncol. 16:1898260. doi: 10.3389/fonc.2026.1898260 November 1, 2026.
Overview
This review explains the principles and bone-marrow applications of multiplex immunohistochemistry (mIHC), comparing it with flow cytometry, mass cytometry, imaging mass cytometry, and spatial transcriptomics. It examines how spatial immune profiling could support risk stratification, clarify CAR T-cell resistance, and advance precision immuno-oncology in multiple myeloma.
"Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps."
Source
Qi Q, Han B, Fu R. Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps. Onco Targets Ther. 2026;19:653346 https://doi.org/10.2147/OTT.S653346 November 1, 2026.
Overview
This narrative review integrates clinical trials, commercial cohorts, translational studies, and treatment-delivery evidence to examine these failures from treatment selection to durable benefit. Reporting across treatment stages can complement response and survival endpoints by distinguishing aggressive disease, insufficient exposure, competing morbidity, and treatment-delivery constraints.
"Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events."
Source
Caitlin Unkenholz, Esther Ortega-Vida, Jorge Monge, Christian A. Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros, Mateo Mejia Saldarriaga; Abnormal serum immunofixation patterns are common after BCMA CAR-T in multiple myeloma and are preceded by immune events. Blood Neoplasia 2026; 3 (4): 100267. doi: https://doi.org/10.1016/j.bneo.2026.100267 November 1, 2026.
Overview
This letter characterizes abnormal serum immunofixation patterns after BCMA-directed CAR T-cell therapy and examines their relationship with survival, hypogammaglobulinemia, infections, and vaccination-related immune stimulation. The authors studied 58 treated patients and call for larger studies to validate whether these patterns reflect immune reconstitution and help identify infection risk.
"Diagnosis and management of monoclonal gammopathies."
Source
Khalife R, Lee A, Jimenez-Zepeda VH, Visram A. Diagnosis and management of monoclonal gammopathies. CMAJ. 2026 Nov 1;198(38):E1469-E1475. doi: 10.1503/cmaj.251482. November 1, 2026.
Overview
This evidence-based clinical review guides generalists in recognizing, evaluating, and following monoclonal gammopathy of undetermined significance and related monoclonal gammopathies of clinical significance. It emphasizes risk-stratified surveillance and referral when clinical or laboratory findings suggest organ injury or progression.
"Incidence and Risk Factors of Hypokalemia in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Collection."
Source
B. Wei, J. Xia, Z. Zheng, Q. Huang, and J. Liu, “Incidence and Risk Factors of Hypokalemia in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Collection,” Journal of Clinical Apheresis 41, no. 6 (2026): e70205, https://doi.org/10.1002/jca.70205. November 1, 2026.
Overview
The study sought to determine the incidence of hypokalemia following APBSC collection in MM patients and to identify independent risk factors. Preprocedure risk factors (BMI, hematocrit, baseline potassium) may help identify high-risk patients for whom intensified electrolyte monitoring and individualized supplementation strategies are warranted.
"The Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM): translation and cross-cultural adaptation into Danish and Norwegian and initial psychometric evaluation of the Norwegian version."
Source
Rosenberg, T., Rutherford, C., King, T. et al. The Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM): translation and cross-cultural adaptation into Danish and Norwegian and initial psychometric evaluation of the Norwegian version. Qual Life Res 35, 317 (2026). https://doi.org/10.1007/s11136-026-04415-5 November 1, 2026.
Overview
This study translated and culturally adapted the Steroid Symptom Questionnaire-Multiple Myeloma into Danish and Norwegian and performed an initial psychometric evaluation of the Norwegian version. The Norwegian questionnaire showed preliminary reliability, validity, and responsiveness, supporting further use and validation in clinical research.
"Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors."
Source
Wei Tan, Jianliang Dai, Chutima Kunacheewa, Melody R. Becnel, Hans C. Lee, Krina K. Patel, David A. Berrios Nolasco, Mei Huang, Amishi U. Vora, Sheeba K. Thomas, Oren Pasvolsky, Zuzana Lutter-Berka, Isere Kuiatse, Neha S. Korde, Sundar Jagannath, Ola Landgren, Suyu Liu, Elisabet E. Manasanch, Robert Z. Orlowski; Soluble B-cell maturation antigen as a biomarker of progression and treatment response in patients with myeloma precursors. Blood Neoplasia 2026; 3 (4): 100284. doi: https://doi.org/10.1016/j.bneo.2026.100284 November 1, 2026.
Overview
Researchers aimed to prospectively investigate whether sBCMA levels could serve as a marker for monitoring disease progression and assessing treatment response in patients with myeloma precursor disease. Future prospective studies with larger patient populations are necessary to validate these findings and hypotheses.
"Real-world evidence supporting sustainable CAR-T-cell therapy-from access to long-term follow-up."
Source
Jo, T. Real-world evidence supporting sustainable CAR-T-cell therapy-from access to long-term follow-up. Int J Hematol (2026). https://doi.org/10.1007/s12185-026-04305-z November 2, 2026.
Overview
This review summarizes major RWE for CAR-T therapies and discusses how RWE can support operational optimization from access through long-term follow-up. Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory B-cell malignancies and multiple myeloma.
"Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis."
Source
Anderson, L.D., Nair, S., Keng, M.J. et al. Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis. Adv Ther (2026). https://doi.org/10.1007/s12325-026-03832-9 November 2, 2026.
Overview
In the phase 3 MajesTEC-3 study (NCT05083169), teclistamab with daratumumab (Tec- Dara) significantly improved progression-free and overall survival (PFS/OS) versus investigator’s choice of standard-of-care daratumumab/pomalidomide/dexamethasone (DPd) or daratumumab/bortezomib/dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy (pLOTs). Patient characteristic imbalances were adjusted for using IPTW. These results further support Tec-Dara as a new standard-of-care regimen for RRMM as early as second-line treatment.
"Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study."
Source
O’Donnell, E.K., Nadeem, O., Laubach, J.P. et al. Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study. Blood Cancer J. 16, 195 (2026). https://doi.org/10.1038/s41408-026-01656-y November 2, 2026.
Overview
This prospective multicenter phase 2 letter evaluated denosumab as bone-supportive therapy for patients with multiple myeloma and severe renal impairment who were not eligible for bisphosphonates. The study assessed suppression of bone resorption and safety during 12 monthly cycles, addressing an evidence gap in a population excluded from the pivotal randomized trial.
"Predictors of Malnutrition in Patients With Multiple Myeloma: A Review of the Literature."
Source
Dubaj M, Bigosiński K, Szudy-Szczyrek A, Małecka-Massalska T, Homa-Mlak I. Predictors of Malnutrition in Patients With Multiple Myeloma: A Review of the Literature. Med Sci Monit. 2026 Nov 3;32:e954862. doi: 10.12659/MSM.954862.
Overview
This narrative review aims to critically summarize and compare current evidence on inflammatory and genetic predictors of malnutrition and cancer cachexia in multiple myeloma, with particular emphasis on the strength of evidence, clinical applicability, and future translational potential. Current evidence therefore supports a clearer near-term clinical potential for inflammation-related biomarkers, whereas molecular predictors remain predominantly investigational and require prospective validation.
"Phase 2 Trial of Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma."
Source
Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase 2 Trial of Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple 89 Myeloma. Radiology. 2026 Nov;321(2):e260517. doi: 10.1148/radiol.260517.
Overview
To compare 89Zr-DFO-daratumumab PET/CT against standard-of-care fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT for detection of MM. Participants with MM were accrued to this prospective phase 2 trial between March 2022 and July 2025. In participants with MM, CD38-targeted 89Zr-DFO-daratumumab immuno-PET helped detect active myeloma in some participants with no signs of disease at 18F-FDG PET/CT.
"Novel insights into the bone microenvironment in myeloma bone disease."
Source
Franziska Jundt, Wen-Hui Cheng, Poonam Kumari, Heike Weidner, Luise Fischer, Maximilian Merz, Andreas Beilhack, Martin Kuric, Regina Ebert, Novel insights into the bone microenvironment in myeloma bone disease, Journal of Bone Oncology, 2026, 100815, ISSN 2212-1374, https://doi.org/10.1016/j.jbo.2026.100815. November 3, 2026.
Overview
This review describes how multiple myeloma alters the bone microenvironment, including extracellular matrix, immune niches, osteocyte architecture, mechanosensing, and bone material quality. It considers how antimyeloma therapies and emerging biophysical approaches may modulate osteoclasts, osteoblasts, and osteoimmune interactions to promote skeletal repair.
"Blood-Based Mass Spectrometry in Plasma Cell Disorders: From Residual Secretory Activity to Multimodal Residual Disease Assessment."
Source
Xuelin Han, Tongtong Liu, Yajing Zhang, Blood-Based Mass Spectrometry in Plasma Cell Disorders: From Residual Secretory Activity to Multimodal Residual Disease Assessment, Critical Reviews in Oncology/Hematology, 2026, 105684, ISSN 1040-8428, https://doi.org/10.1016/j.critrevonc.2026.105684. November 3, 2026.
Overview
This critical review examines the analytical basis, biological interpretation, and clinical evidence for blood-based MS in multiple myeloma, AL amyloidosis, and related plasma cell disorders. Current evidence supports prognostic validity and longitudinal monitoring, but treatment-guiding clinical utility remains unproven.
"Spatial Profiling Identifies a Distinct and Topographically Defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution."
Source
Marnix Koops, Luca Bertamini, Natalie Papazian, Charlotte Korst, Mátyás János Budai, Remco M. Hoogenboezem, Mathijs A. Sanders, Bronno van der Holt, Mark van Duin, Annemiek Broijl, Péter Balogh, Sonja Zweegman, Marc H.G.P. Raaijmakers, Niels W.C.J. van de Donk, Zoltán Kellermayer, Pieter Sonneveld, Tom Cupedo; Spatial Profiling Identifies a Distinct and Topographically Defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution. Blood Cancer Discov 1 November 2026; 7 (6): 999-1016. https://doi.org/10.1158/2643-3230.BCD-26-0080
Overview
The pathobiology of multiple myeloma is influenced by cells of the bone marrow (BM), but whether tumor support is organized in a spatially defined tumor microenvironment (TME) remains unclear. Using spatial transcriptomics and imaging mass cytometry, researchers show that myeloma cells initially exist as scattered cells throughout the marrow, yet with disease evolution condense into a spatially defined TME.
"Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing."
Source
Xiong X, Wang X, Li J, Shen K. Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261503783 November 3, 2026.
Overview
In 2025, three landmark cohort studies using whole-exome or whole-genome sequencing (WES/WGS) proposed distinct but relevant genomic frameworks for reclassifying disease risk in MGUS and SMM. Despite differences in design and analyses, these frameworks converge on several principles: (i) the malignant genomic architecture of myeloma is established well before clinical progression; (ii) a substantial fraction of clinically defined precursor disease already harbors the hallmarks of overt myeloma; and (iii) WES/WGS-derived features meaningfully improve clinical risk models.
"Spatial transcriptomics and proteomics determinants of resistance to T cell engagers in extramedullary multiple myeloma."
Source
Jeong Nam H, D’Souza D, Roche R, Radkevich E, Bi C, Parikh I, et al. 148 Spatial transcriptomics and proteomics determinants of resistance to T cell engagers in extramedullary multiple myeloma. Journal for ImmunoTherapy of Cancer. 2026;14:. https://doi.org/10.1136/jitc-2026-SITC2026.0148 November 3, 2026.
Overview
This spatial transcriptomic and proteomic study investigated the tumor microenvironment and mechanisms of resistance to CAR T-cell and bispecific T-cell engager therapy in extramedullary multiple myeloma. The findings implicate heterogeneous target expression, limited T-cell trafficking, and immunosuppressive macrophage niches, suggesting that macrophage modulation and improved T-cell homing may help overcome resistance.
"Metabolomic and lipidomic analyses reveal early biomarkers linked to treatment response to BCMA-TCE in patients with relapsed/refractory multiple myeloma."
Source
G Thompson E, Stancliffe E, Gandhi M, Martin N, Godwin C, Kaiser S, et al. 485 Metabolomic and lipidomic analyses reveal early biomarkers linked to treatment response to BCMA-TCE in patients with relapsed/refractory multiple myeloma. Journal for ImmunoTherapy of Cancer. 2026;14:. https://doi.org/10.1136/jitc-2026-SITC2026.0485. November 3, 2026.
Overview
The report describes untargeted metabolomic and lipidomic analysis identifying biomarkers associated with response to alnuctamab (ALNUC1; CC-93269) and stratifying responders by durability. These findings support differential systemic metabolic states associated with response.
"Discordant marrow MRD and PET-CT in myeloma: A four-state language for joint reporting."
Source
Mendez-Lopez M, Talarico M, Zamagni E, Lehmann T. Discordant marrow MRD and PET-CT in myeloma: A four-state language for joint reporting. Br J Haematol. 2026; 00: 1-3. https://doi.org/10.1111/bjh.70933 November 3, 2026.
Overview
This report proposes a four-state framework for jointly interpreting bone marrow measurable residual disease and PET-CT results in multiple myeloma. Its purpose is to make discordant findings clinically reportable and more useful for response assessment, endpoint interpretation, and response-adapted trial design.
"Prognostic significance of IgG-Kappa positivity detected by serum immunofixation during daratumumab therapy in multiple myeloma."
Source
Cengiz E, Kırcalı E, Aydın RF, Çınarsoy M. Prognostic significance of IgG-Kappa positivity detected by serum immunofixation during daratumumab therapy in multiple myeloma. Ups J Med Sci. 2026 Nov 3;131. doi: 10.48101/ujms.v131.14932
Overview
Researchers therefore evaluated treatment responses and the prognostic impact of daratumumab-associated IgG-κ IF positivity on progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Researchers retrospectively analyzed 108 patients with MM treated with daratumumab-containing regimens at any line of therapy between January 2014 and January 2024. Recognizing this interference is important to avoid overestimating residual disease and misclassifying treatment response, and confirmatory assays should be used where available.
"ALDH2 functions as an independent favorable prognostic biomarker and suppresses multiple myeloma progression through regulation of the E2F signaling pathway."
Source
Cai, L., Chen, D., Zhou, Y. et al. ALDH2 functions as an independent favorable prognostic biomarker and suppresses multiple myeloma progression through regulation of the E2F signaling pathway. Discov Onc (2026). https://doi.org/10.1002/advs.78403 November 3, 2026.
Overview
This study aimed to investigate the clinical significance and functional role of ALDH2 in MM and to elucidate its regulatory mechanism in tumor progression. Single-cell RNA sequencing data (GSE271107) identified differentially expressed genes in plasmacytoid dendritic cells (pDCs) between MM patients and healthy donors. These findings provide mechanistic insight into microenvironment-associated metabolic regulation in MM and highlight ALDH2 as a potential therapeutic target.
"Targeting the circ_0042819-PLA2G6 axis sensitizes multiple myeloma to proteasome inhibitors through ferroptosis induction."
Source
Ren, H., Liu, C., Wang, Z. et al. Targeting the circ_0042819-PLA2G6 axis sensitizes multiple myeloma to proteasome inhibitors through ferroptosis induction. Cell Death Differ (2026). https://doi.org/10.1038/s41418-026-01847-x November 3, 2026.
Overview
This preclinical study investigated whether inhibiting the circ_0042819-PLA2G6 axis could restore proteasome-inhibitor sensitivity in multiple myeloma by promoting ferroptosis. The findings identify circ_0042819 as a potential biomarker and the axis as a candidate therapeutic target for overcoming drug resistance.
"Integration of peripheral blood lymphocyte subsets and cytokines enhances prognostic stratification in newly diagnosed multiple myeloma."
Source
Zhao X, Liu Z, Qin G, Wang J, Liu H, Ding K, et al. Integration of peripheral blood lymphocyte subsets and cytokines enhances prognostic stratification in newly diagnosed multiple myeloma. Br J Haematol. 2026; 00: 1-9. https://doi.org/10.1111/bjh.70932 November 4, 2026.
Overview
This study developed an immune risk score that combines peripheral blood lymphocyte subsets and cytokines to improve prognostic stratification in newly diagnosed multiple myeloma. CD3+CD8+ T-cell counts and interleukin-10 contributed to a nomogram that outperformed established staging systems in exploratory analyses.
"Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: current clinical applications, challenges and future directions."
Source
Manzato E, Cocchetto G, Barbato S, Puppi M, Masci S, Zamagni E. Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: current clinical applications, challenges and future directions. Cancer. 2026;e70641. doi:10.1002/cncr.70641 November 4, 2026.
Overview
Overall, the objective of this review was to provide a comprehensive overview on the role of BCMA-targeting bsAbs while discussing future developments in this field, including their use across different settings and combinations strategies, as well as the ongoing efforts to improve safety and tolerability through the implementation of specific guidelines for toxicity management. Anti-B cell maturation antigen (BCMA) therapies, including antibody-drug conjugates, chimeric antigen receptor T cells, and bispecific antibodies (bsAbs), have recently revolutionized the treatment landscape of multiple myeloma.
"The Cytotoxic Activity of Bis(α-aryl-methylphosphonoyl)amines and Derivatives Obtained by the Tandem Kabachnik-Fields Reaction on Human Multiple Myeloma Cell Line U266."
Source
Bajusz, B., Karaghiosoff, K., Kőhidai, L., Takács, A., & Keglevich, G. (2026). The Cytotoxic Activity of Bis(α-aryl-methylphosphonoyl)amines and Derivatives Obtained by the Tandem Kabachnik-Fields Reaction on Human Multiple Myeloma Cell Line U266. Pharmaceuticals, 19(11), 1748. https://doi.org/10.3390/ph19111748 November 4, 2026.
Overview
This laboratory study synthesized a series of bis(α-aryl-methylphosphonoyl)amines and related compounds and tested their cytotoxicity against U266 human multiple myeloma cells. Most compounds had limited activity, but one chlorophenyl derivative markedly reduced viability, supporting further structure-activity investigation.
"Targeting Nuclear Export in Multiple Myeloma: Selinexor, Emerging XPO1 Inhibitors, and Future Therapeutic Strategies."
Source
Kul, S., Eminoglu, H., Altinoz, B. N., Zorlu, T., Candir, B. A., Ulas, T., & Dal, M. S. (2026). Targeting Nuclear Export in Multiple Myeloma: Selinexor, Emerging XPO1 Inhibitors, and Future Therapeutic Strategies. Pharmaceutics, 18(11), 1431. https://doi.org/10.3390/pharmaceutics18111431 November 4, 2026.
Overview
Particular attention was given to pivotal and clinically relevant studies evaluating selinexor-based regimens, including Selinexor Treatment of Refractory Myeloma (STORM), BOSTON, and combination cohorts from the STOMP program, together with recent translational studies expanding the molecular framework of XPO1 inhibition. Increasing use of lower-dose, onceweekly combination strategies has improved its therapeutic feasibility, while emerging insights into XPO1 degradation, metabolic regulation, and molecular determinants of response are broadening the biological framework of this drug class.
"Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery."
Source
Andrews RE, Jolley I, Evans H, Lath D, Sharma V, Brown JE, et al. Bone recovery after treatment study: Evidence of myeloma bone disease repair and partial microenvironment recovery. Br J Haematol. 2026; 00: 1-11. https://doi.org/10.1111/bjh.70903 November 4, 2026.
Overview
This pilot study assessed the feasibility of longitudinally measuring bone recovery in newly diagnosed myeloma patients receiving first-line therapy (e.g. induction ± autologous stem cell transplant, plus zoledronic acid), as a prelude to formally assessing bone anabolic strategies. These data highlight the ongoing need for novel, bone-targeted therapies to support MBD recovery.
"Circulating Multiple Myeloma Cell Kinetics and Genomic Profiling Predict Resistance to Targeted Immunotherapies."
Source
Binod Dhakal, Michael Slade, Alberto Ferrarini, Paola Tononi, Marla Ruzicka, Aniko Szabo, Othman Akhtar, Jasper Olsem, Ravi Narra, Mark Schroeder, Hima Bansal, Maria Jose Acevedo-Calado, Oren Pasvolsky, Mahmoud R. Gaballa, Khanmi Kasomva, Melody R. Becnel, Donna M. Weber, Krina K. Patel, Sheeba K. Thomas, J Christine Ye, Meera Mohan, Fumou Sun, Zoltan Simandi, Sabari Radhakrishnan, Keith Stockert-Goldtsein, Wojciech Swat, Frank Kuhr, Ravi Vij, Federica Sola, Giuseppe Giacomo Montefrancesco, Marianna Garonzi, Nicolò Manaresi, Anita D’Souza, Robert Z Orlowski, Hans C. Lee; Circulating Multiple Myeloma Cell Kinetics and Genomic Profiling Predict Resistance to Targeted Immunotherapies. Blood Neoplasia 2026; 100332. doi: https://doi.org/10.1016/j.bneo.2026.100332 November 4, 2026.
Overview
This prospective study evaluated circulating multiple myeloma cell kinetics and genomic profiling as a minimally invasive way to monitor patients receiving BCMA- or GPRC5D-directed bispecific antibodies. Early cell-clearance patterns tracked response, while blood-based sequencing identified high-risk alterations and antigen-loss mechanisms that could signal emerging resistance.
"Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma."
Source
Daniel Gomes, Phillip Sarocco, Charles P. Theuer, Gareth Morgan, Todd Kennedy, Paul Santos Estrella, Jimmy Zhou, Saad Z. Usmani, Increased Overall Survival for Subcutaneous Versus Intravenous Daratumumab in Medicare Beneficiaries With Multiple Myeloma, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.08.016. November 4, 2026.
Overview
Daratumumab has improved survival outcomes for patients with multiple myeloma (MM), but the effect of administration route on rwOS remains unclear. Eligible patients enrolled in Medicare aged ≥ 65 years were continuously enrolled in Parts A, B, and D for ≥ 12 months before daratumumab initiation. Overall, Dara PH20 SC was associated with improved rwOS versus Dara IV in Medicare beneficiaries with MM, which appears to be driven by lower risk of serious infections and longer treatment duration with Dara PH20 SC.
"MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma."
Source
Carmen Gonzalez, Camila Guerrero, Marta Larrayoz, Aintzane Zabaleta, Junfei Zhao, Ioannis V. Kostopoulos, Ourania E. Tsitsilonis, Evangelos Terpos, Norma C. Gutiérrez, Manuela Fernández, María-José Calasanz, Paula Rodriguez- Otero, Felipe Prosper, Teresa Lozano, Juan-José Lasarte, Benjamin L. Ebert, Albert Oriol, Anna Sureda, Maria-Jesus Blanchard, Yolanda Gonzalez, Joan Bargay, Sunil Lakhwani, Rafael Rios-Tamayo, Laura Rosiñol, Joaquin Martinez- Lopez, Juan-José Lahuerta, Joan Blade, Maria-Victoria Mateos, Jesús F. San Miguel, Maria-Teresa Cedena, Noemi Puig, Patrick Hagner, Maria Ortiz, José Angel Martinez-Climent, Bruno Paiva; MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma. Blood 2026; 148 (19): 2368-2383. doi: https://doi.org/10.1182/blood.2026033878 November 5, 2026.
Overview
This study used serial measurable residual disease assessments to define patterns of MRD dynamics, identify patients with MRD-resistant disease, and test the biological rationale for intervening before clinical relapse. The results suggest that repeated MRD profiling can identify a vulnerable disease state in which immunotherapy may be more effective than treatment delayed until relapse.
"Combination antiviral treatment for a patient with lymphocytic choriomeningitis virus meningoencephalitis associated with bispecific antibody teclistamab therapy for myeloma."
Source
Maamari RG, Williams TGS, Zheng C, Hack B, Tomkins O, Bakrania P, Thangarajah R, Ringue I, Storey N, Brown JR, Morfopoulou S, Solas C, Néant N, Daddiego J, Okonkwo V, Chandra J, Rampling T, Houlihan CF, Breuer J, Milligan I, Douthwaite S, Streetly M, Vaghela D. Combination antiviral treatment for a patient with lymphocytic choriomeningitis virus meningoencephalitis associated with bispecific antibody teclistamab therapy for myeloma. Lancet Infect Dis. 2026 Nov 5:S1473- 3099(26)00479-2. doi: 10.1016/S1473-3099(26)00479-2. Epub ahead of print.
Overview
The report describes a presentation of LCMV meningoencephalitis in a patient with relapsed multiple myeloma receiving teclistamab. Finally, the case provides preliminary evidence supporting combination antiviral therapy in persistent LCMV infection.
"Cyclophosphamide maintenance in multiple myeloma without transplantation: A real-world study."
Source
Qian Zhao, Siqi Qian, Jiangang Mei, Jing Zhang, Ping Song, Zhiming An, Xuli Wang, Feng Li, Cyclophosphamide maintenance in multiple myeloma without transplantation: A real-world study, Leukemia Research, Volume 171, 2026, 108359, ISSN 0145-2126, https://doi.org/10.1016/j.leukres.2026.108359. November 5, 2026. .
Overview
Researchers compared response deepening, progression-free survival (PFS), overall survival (OS), safety, and cost. In conclusion, Cytoxan (cyclophosphamide, or CTX) monotherapy maintenance achieves comparable PFS and OS to lenalidomide in NDMM patients without transplantation, with manageable toxicity and dramatically lower cost, suggesting that CTX monotherapy may represent a viable and cost-effective alternative particularly in resourcelimited settings.
"Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma."
Source
Qaiser Bashir, Peter F. Thall, Jitesh D. Kawedia, Xun Xu, Cristina G. Knape, Ruby Delgado, Yago Nieto, Neeraj Saini, Yosra M. Aljawai, Samer A. Srour, Varga C, Schaefer E. Practical Recommendations for Implementing Remote Patient Monitoring for Patients Receiving Bispecific Antibodies for Multiple Myeloma, JMIR Cancer 2026;12:e95949 doi: 10.2196/95949 PMID: 42987260 November 5, 2026.
Overview
In this Viewpoint, researchers aim to provide practical recommendations built from our own real-world perspectives and case examples for institutions seeking to implement remote patient monitoring (RPM) strategies to support the outpatient dosing of bispecific antibodies in patients with MM. While specific approaches will vary based on the needs of each treatment center, our experiences suggest that RPM implementation can be safe and feasible for both academic and community practices.
"Achievement and Persistence of MRD Negativity with Anti-CD38-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta-Analysis."
Source
Caridà, G., Scalise, L., Mosca, A., De Fazio, L., Costa, M., Molica, M., & Rossi, M. (2026). Achievement and Persistence of MRD Negativity with Anti-CD38-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Network Meta- Analysis. Cancers, 18(21), 3573. https://doi.org/10.3390/cancers18213573 November 6, 2026.
Overview
Researchers conducted a systematic review and frequentist random-effects network meta-analysis (NMA) of randomized trials reporting MRD negativity by treatment arm; sustained MRD (sMRD) negativity was analyzed by pairwise meta-analysis. Anti-CD38-based quadruplets offer the highest probability of achieving MRD negativity and improve its persistence regardless of transplant eligibility, whereas the incremental contribution of ASCT in the quadruplet era remains uncertain.
"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0."
Source
Lin Y, Aiello J, Avigan D, Berdeja JG, Biru Y, Chari A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma, version 2.0. Journal for ImmunoTherapy of Cancer. 2026;14:e016142. https://doi.org/10.1136/jitc-2026-016142 November 6, 2026.
Overview
To provide guidance to the hematology and medical oncology community, the Society for Immunotherapy of Cancer convened a multidisciplinary panel of experts to develop a clinical practice guideline. There are many practical and clinical considerations to take into account for CAR T-cell, TCE, and ADC therapy administration, safety management, and treatment sequencing, making clinical decisions complex and nuanced.
"Multiple Myeloma in a Resource-Limited Setting: Clinical Presentation, Treatment Patterns, and Outcomes From a 99-Patient Cohort in Senegal."
Source
N. Dieng, M. Keita, K. M. Youmssi, et al. “Multiple Myeloma in a Resource-Limited Setting: Clinical Presentation, Treatment Patterns, and Outcomes From a 99-Patient Cohort in Senegal.” eJHaem 7, no. 6 (2026): e70402. https://doi.org/10.1002/jha2.70402 November 6, 2026.
Overview
The study aimed to characterize the clinical presentation, treatment strategies, and outcomes of MM patients managed in a resource-limited setting. These findings highlight persistent global disparities in MM care and underscore the urgent need for adapted diagnostic and therapeutic strategies, and for strategies to reduce loss to follow-up, in low- and middle-income countries.
"IGFBP5 negatively regulates adhesion-mediated bortezomib resistance and modulates FAK/Src signaling in multiple myeloma."
Source
et al. IGFBP5 negatively regulates adhesion-mediated bortezomib resistance and modulates FAK/Src signaling in multiple myeloma. Clin Exp Med (2026). https://doi.org/10.1007/s10238-026-02383-1 November 6, 2026.
Overview
Researchers integrated public gene-expression datasets (GSE6477, GSE31161, GSE136400, and GSE4204) with analyses of primary bone marrow samples. These findings identify IGFBP5 as a candidate molecular target for further investigation into microenvironment-associated drug resistance in multiple myeloma.
"Succinate promotes multiple myeloma cell proliferation through TCA cycle oxidation."
Source
Gudgeon N, Fulton-Ward T, Stavrou V, Haslam A, McIlroy G, Giles H, Pratt G, Dimeloe S. Succinate promotes multiple myeloma cell proliferation through TCA cycle oxidation. Cell Rep. 2026 Nov 6;45(11):118267. doi: 10.1016/j.celrep.2026.118267. Epub ahead of print.
Overview
This study examined how extracellular succinate supports multiple myeloma growth and whether mitochondrial succinate transport and oxidation create a therapeutic vulnerability. The findings link succinate metabolism with plasma-cell proliferation and identify the transport pathway as a potential treatment target.
"Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis."
Source
Korpás, L., Wiedemann, Á., Szél, F., Svorenj, S., Weisinger, J., Nagy, Z., Szemlaky, Z., Csukly, Z., Reményi, P., Rajnics, P., Altai, E., Plander, M., Kórád, K., Szaleczky, E., Masszi, A., Kosztolányi, S., Alizadeh, H., Modok, S., Borbényi, Z., . Varga, G. (2026). Lower Dexamethasone Dose in Multiple Myeloma: A Multicenter Retrospective Analysis. Cancers, 18(21), 3565. https://doi.org/10.3390/cancers18213565 November 6, 2027.
Overview
This retrospective, multicenter study aimed to evaluate the impact of varied dexamethasone dosing regimens on clinical outcomes within a real-world setting. Lower initial dexamethasone dose was not associated with statistically significant differences in progression-free survival or treatment response in this retrospective cohort.
"Going beyond CRAB: An exploratory assessment of bortezomib response and miRNA biomarkers in African American men with multiple myeloma."
Source
Bamfield-Cummings Shafisha, Benjamin Tiffany, A. Karim Zubair, Silva Jeane, Going beyond CRAB: An exploratory assessment of bortezomib response and miRNA biomarkers in African American men with multiple myeloma, Human Gene, 2026, 201619, ISSN 2773-0441, https://doi.org/10.1016/j.humgen.2026.201619. November 7, 2026.
Overview
To identify novel intramedullary ncRNA biomarkers predictive of intrinsic bortezomib (BTZ) resistance and define the associated clinical phenotype and health-related quality of life (HRQoL) impairment. Researchers used an integrated approach that combined clinical phenotyping, patient-reported outcomes, and molecular biomarker discovery. Such an approach enables earlier detection of treatment resistance, personalized clinical management, and reduced disparities in patient outcomes.
"Epitranscriptomic regulation contributes to multiple myeloma biology and offers potential therapeutic targets."
Source
Amr Ali Mohamed Abdelgawwad El-Sehrawy, Saja Khalil Ibrahim, Sarmad S. Abdullah, Ahmed Hjazi, Priya Priyadarshini Nayak, Navin Kumar Tailor, Aseel Smerat, Salamn M. Abd, Tina Saeed Basunduwah, Chou-Yi Hsu, Epitranscriptomic regulation contributes to multiple myeloma biology and offers potential therapeutic targets, Neoplasia, 2026, 101396, ISSN 1476-5586, https://doi.org/10.1016/j.neo.2026.101396. November 7, 2026.
Overview
RNA modifications are being investigated as contributors to multiple myeloma (MM) biology alongside genomic lesions and bone marrow interactions. Epitranscriptomic regulation therefore offers a useful research framework for understanding and potentially targeting MM, without displacing the established contribution of genomic and clinical risk factors.
"Influence of CAR T-cell expansion and persistence in the peripheral blood on CAR T-cell therapy efficacy and adverse events in multiple myeloma."
Source
Boettger, M., Sauerborn, P., Ihorst, G. et al. Influence of CAR T-cell expansion and persistence in the peripheral blood on CAR T-cell therapy efficacy and adverse events in multiple myeloma. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-03083-w November 7, 2026.
Overview
Researchers analyzed the clinical outcome and the influence of BCMA-CAR T-cell expansion in peripheral blood (PB) by flow cytometry in our first 40 CAR T-treated multiple myeloma (MM) patients (cilta-cel n = 28, ide-cel n = 12) (Supplementary Table S1). Greater CAR T-cell expansion, particularly following cilta-cel infusion, was associated with deeper responses, whereas no significant association with PFS or OS was observed, but may also increase the risk of ICANS.
"Genomic, single-cell, and functional profiling of the CD48-CD244 axis and NK cell dysfunction in multiple myeloma."
Source
Patiño-Escobar B, Steinbrunn T, Perez-Lugo L, Rampersaud S, Waller DD, Ordoñez D, Geng H, Salangsang F, Phojanakong P, Camara Serrano JA, Zeng Y, Steri V, Aguilar OA, Mitsiades CS, Wiita AP. Genomic, single-cell, and functional profiling of the CD48-CD244 axis and NK cell dysfunction in multiple myeloma. JCI Insight. 2026 Nov 9;11(21):e203794. doi: 10.1172/jci.insight.203794.
Overview
Multiple myeloma (MM) orchestrates immune evasion by subverting natural killer (NK) cell function. These findings support a context-dependent role for CD48, potentiating acute NK responses while coexisting with chronic NK exhaustion, and suggest strategies to modulate CD48 for therapeutic benefit.
"Monoclonal Gammopathy of Neurologic Significance: A Practical Framework for Diagnosis and Management."
Source
Manisha Bhutani et al. Monoclonal Gammopathy of Neurologic Significance: A Practical Framework for Diagnosis and Management. JCO Oncol Pract 0, OP-26- 00658 DOI:10.1200/OP-26-00658 November 9, 2026.
Overview
This practical review provides a diagnostic and management framework for monoclonal gammopathy of neurologic significance, in which a monoclonal protein is implicated in peripheral neuropathy. Representative IgM and non-IgM cases illustrate how neurologic phenotype, paraprotein features, and multidisciplinary assessment can guide treatment decisions.
"Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone."
Source
Pieter Sonneveld et al. Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone. J Clin Oncol 0, JCO-26-00384 DOI:10.1200/JCO-26-00384 November 9, 2026.
Overview
This modeling study extrapolated progression-free survival from the PERSEUS and CEPHEUS trials to estimate long-term outcomes with daratumumab, bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Its purpose was to assess the durability of benefit beyond observed follow-up using alternative parametric survival models.
"Monoclonal gammopathy of clinical significance: the pathogenic paraprotein and a precision medicine roadmap."
Source
Soleimani Samarkhazan, H., Bahmani, F., Rayati, M., Taheri Zare, Z., Emadi, R., Shirgholami, Z., & Mohammadi, M. H. (2026). Monoclonal gammopathy of clinical significance: the pathogenic paraprotein and a precision medicine roadmap. Hematology, 31(1). https://doi.org/10.1080/16078454.2026.2755113 November 9, 2026.
Overview
This review aims to decode the mechanisms of paraprotein-mediated organ injury, chart the diverse clinical spectrum of MGCS, integrate modern diagnostic approaches, and propose a precision medicine roadmap for targeted therapeutic intervention. Study quality was appraised using designspecific domains (risk of bias, sample size, diagnostic ascertainment, confounding, followup, statistical reporting, and directness); because of heterogeneity, no meta-analysis was performed, and evidence was synthesized narratively with qualitative certainty ratings. Multidisciplinary collaboration and integration of multi-omics with artificial intelligence hold promise for improved risk stratification.
"Carfilzomib in Contemporary Multiple Myeloma: Contextualising Efficacy, Toxicity, and Treatment Sequencing."
Source
H., Meshal Almalki, M., Mohamad Safwan Almassri, A., & Bashir Ibrahim Elbashir, I. (2026). Carfilzomib in Contemporary Multiple Myeloma: Contextualising Efficacy, Toxicity, and Treatment Sequencing. Hemato, 7(4), 43. https://doi.org/10.3390/hemato7040043 November 9, 2026.
Overview
This review evaluates carfilzomib efficacy, toxicity, dosing, and sequencing across contemporary multiple myeloma regimens. It aims to clarify which patients and treatment settings may offer the most favorable benefit-risk balance while acknowledging that cross-trial regimen differences limit direct attribution.
"Complementary Role of Soluble BCMA and Circulating Tumor Plasma Cells as Peripheral Blood Biomarkers in Newly Diagnosed Multiple Myeloma."
Source
Gupta, P., Jain, A., Sachdeva, M.U.S. et al. Complementary Role of Soluble BCMA and Circulating Tumor Plasma Cells as Peripheral Blood Biomarkers in Newly Diagnosed Multiple Myeloma. Indian J Hematol Blood Transfus (2026). https://doi.org/10.1007/s12288-026-02624-z November 10, 2026.
Overview
This study evaluated soluble BCMA and circulating tumor plasma cells as complementary, minimally invasive biomarkers for monitoring newly diagnosed multiple myeloma. Soluble BCMA showed promise for dynamic response assessment, while circulating tumor plasma cells were associated with high-risk cytogenetic features.
"Risk Stratification of Newly Diagnosed Multiple Myeloma: Predictive Value of First-Year Biomarker Trajectories Identified by Group-Based Trajectory Modeling."
Source
H. Bai, W. Tang, Y. Li, et al., “Risk Stratification of Newly Diagnosed Multiple Myeloma: Predictive Value of First-Year Biomarker Trajectories Identified by Group-Based Trajectory Modeling,” Cancer Medicine 15, no. 11 (2026): e72503, https://doi.org/10.1002/cam4.72503. November 10, 2026.
Overview
This study aimed to develop a prognostic model incorporating longitudinal biomarker trajectories to improve risk stratification for newly diagnosed MM patients. Researchers retrospectively analyzed 635 patients from West China Hospital between February 1, 2017 and December 30, 2022. This model may help identify high-risk patients and predict long-term survival, offering a valuable tool for personalized treatment planning.
"Integrated bioinformatics and in vitro analyses identify BHLHE40 as a candidate regulator associated with senescence-like growth arrest in multiple myeloma."
Source
Pei Y, Li P, Pu Z, Xu D and Yang W (2026) Integrated bioinformatics and in vitro analyses identify BHLHE40 as a candidate regulator associated with senescence-like growth arrest in multiple myeloma. Front. Oncol. 16:1989759. doi: 10.3389/fonc.2026.1989759 November 10, 2026.
Overview
This study combined bioinformatics, Mendelian randomization, and cell experiments to investigate BHLHE40 as a regulator of senescence-like growth arrest in multiple myeloma. The results support BHLHE40 as a candidate biologic and prognostic marker linked to reduced cell proliferation and immune-microenvironment features.
"Relapse patterns and clinical outcomes after BCMA-directed CAR-T therapy in multiple myeloma: a real-world single-center study."
Source
Bu, Q., Jiang, Y., Zhou, H. et al. Relapse patterns and clinical outcomes after BCMA-directed CAR-T therapy in multiple myeloma: a real-world single-center study. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-17121-9 November 10, 2026.
Overview
Despite deep remissions achieved with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (MM), most patients eventually relapse. This retrospective single-center study included 40 Chinese patients with MM who relapsed after BCMA-directed CAR-T therapy. Extramedullary disease (EMD) relapse was associated with inferior survival and poorer response to salvage therapy, highlighting the need for imaging surveillance in addition to laboratory monitoring during post-CAR-T follow-up.
"Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200."
Source
Jeremy L. Ramdial, Chitra Hosing, Uday R. Popat, Betul Oran, Partow Kebriaei, Sairah Ahmed, Oren Pasvolsky, Krina Patel, Sheeba Thomas, Mahmoud Gaballa, Christine Ye, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash; Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200. Blood Adv 2026; 10 (21): 7218-7229. doi: https://doi.org/10.1182/bloodadvances.2026020293 November 10, 2026.
Overview
Primary objectives included dose/schedule optimization using a Bayesian design and PK characterization; secondary objectives included minimal residual disease (MRD)-negative complete response (CR) at day 90, toxicity, and progression-free survival (PFS). These results support Evomela as a platform for safe dose intensification and AUC-guided conditioning for patients with newly diagnosed myeloma undergoing autologous stem cell transplant (ASCT).
"Challenges of management and outcomes of multiple myeloma in Armenia: A real world experience from a developing country."
Source
Nerses Ghahramanyan, Samvel Bardakhchyan, Astghik Voskanyan, Narine Ghazaryan, Karen Meliksetyan, Karapet Hakobyan, Marine Melik-Andreasyan, Marine Ghazaryan, Miranush Saaryan, Hayk Grigoryan, Samvel Danelyan, Gevorg Tamamyan, Armine Farmazyan, Gevorg Saghumyan, Levon Evoyan, Hasmik Oseyan, Lusine Harutyunyan, Yervand K. Hakobyan, Dickran Kazandjian, Challenges of management and outcomes of multiple myeloma in Armenia: A real world experience from a developing country, Blood Global Hematology, 2026, 100178, ISSN 3050-5658, https://doi.org/10.1016/j.bglo.2026.100178. November 11, 2026.
Overview
The aim of this study is to evaluate diagnostic, treatment challenges, and outcomes of MM in Armenia during the last 7 years. Limited access to novel agents, diagnostic resources, and maintenance therapy contributed to the markedly lower overall survival rates observed in our cohort.
"Association of glycemic index and glycemic load with multiple myeloma: a case-control study."
Source
Abdolkarimi, MJ., Shadnoush, M., Jowshan, MR. et al. Association of glycemic index and glycemic load with multiple myeloma: a case-control study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-80422-3 November 11, 2026.
Overview
The study investigated this relationship in an Iranian population. Higher dietary GI was independently associated with increased odds of MM, whereas dietary GL was not associated with MM after adjustment for energy intake and other confounders.
"Disease perception, quality of life and mental health among Chinese patients with transplant-eligible newly diagnosed multiple myeloma following treatment: a cross-sectional survey study."
Source
Yuanyuan Zhang, Jiawen You, Yuan Meng, Yiming Zhao, Haijun Sun, Jiayi Wang, Chunjia Chen, Guru Sharan Sah, Wendong Chen, Xiaojun Liu, and Jianbo Meng. Disease perception, quality of life and mental health among Chinese patients with transplant-eligible newly diagnosed multiple myeloma following treatment: a cross-sectional survey study. (2026) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2026-0155
Overview
This study evaluated disease perception, health-related quality of life (HRQoL) and mental health among Chinese patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) after treatment in Chinese tertiary hospital settings. HRQoL was generally preserved in treated Chinese patients with NDMM, but anemia was linked to poorer HRQoL and progressive disease to greater anxiety and depression, supporting targeted education and psychosocial care.
"Epidemiological Findings of Multiple Myeloma in the Bronx, New York: 2016 to 2022."
Source
Ruobing Xiao, 254 Epidemiological Findings of Multiple Myeloma in the Bronx, New York: 2016 to 2022, American Journal of Clinical Pathology, Volume 166, Issue Supplement_1, November 2026, aqag106.123, https://doi.org/10.1093/ajcp/aqag106.123
Overview
This epidemiologic study described multiple myeloma cases diagnosed at Montefiore Medical Center from 2016 through 2022, with attention to patient demographics, residence, and mortality. It was intended to characterize the disease burden in the Bronx and inform further investigation of population and environmental risk factors.
"Myeloma patient outcome scale (MyPOS): cross-cultural adaptation and validity evidence for the Brazilian population."
Source
de Lima, M., Filho, C.L., Gonçalves, B.T. et al. Myeloma patient outcome scale (MyPOS): cross-cultural adaptation and validity evidence for the Brazilian population. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-17162-0 November 11, 2026.
Overview
This multicenter methodological study culturally adapted the Myeloma Patient Outcome Scale for Brazil and evaluated its psychometric properties. The Brazilian version showed evidence of validity and internal consistency, supporting its use in clinical practice and research.
"YTHDF2-mediated m6A-dependent decay of DAB2 activates Wnt/β-catenin signaling to promote multiple myeloma proliferation."
Source
Liu, H., Fu, B., Lv, Y. et al. YTHDF2-mediated m6A-dependent decay of DAB2 activates Wnt/β-catenin signaling to promote multiple myeloma proliferation. J Transl Med (2026). https://doi.org/10.1186/s12967-026-09161-3 November 11, 2026.
Overview
This mechanistic study investigated how YTHDF2-mediated m6A-dependent degradation of DAB2 promotes multiple myeloma growth through Wnt/β-catenin signaling. The findings identify DAB2 as a tumor suppressor and the YTHDF2-DAB2-Wnt/β-catenin axis as a potential therapeutic target.
"Validation of an LC-Q-TOF “HiRes Mass-fix” assay for improved sensitivity and specificity of M-protein detection."
Source
Pearce, R., Kohlhagen, M., Martinez, M., Willrich, M., Jevremovic, D., Coker, J. & Murray, D. (2026). Validation of an LC-Q-TOF “HiRes Mass-fix” assay for improved sensitivity and specificity of M-protein detection. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2026-1525 November 11, 2026.
Overview
To validate a blood-based liquid chromatography quadrupole time-of-flight mass spectrometry (MS) method “HiRes Mass-Fix” as a fit-for-purpose, patient-specific method for detecting low-level M-proteins in patients who have reached negativity by MALDI-TOF MS “Mass-Fix”. Analytical validation included precision, accuracy, analytical measurement interval, limit of detection, specificity, ion suppression, carryover, and extracted-sample stability. HiRes Mass-Fix was successfully validated and demonstrated to increase M-protein detection in samples negative by Mass-Fix.
"Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)."
Source
Tan, M.S., Wong, K.L., Soekojo, C. et al. Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010). Blood Cancer J. 16, 201 (2026). https://doi.org/10.1038/s41408-026-01641-5 November 11, 2026.
Overview
This multicenter Asian study described real-world treatment patterns and outcomes across successive lines of therapy for relapsed or refractory multiple myeloma. It highlights regional variation and progressively shorter progression-free survival with later treatment and greater drug-class refractoriness.
"Understanding multiple myeloma: insights into patients’ experiences and preferences for communication, information and support."
Source
Harder, H., Hunter, R., Collinson, B., Jones, J., Street, T., Evans, C., … Jenkins, V. (2026). Understanding multiple myeloma: insights into patients’ experiences and preferences for communication, information and support. Hematology, 31(1). https://doi.org/10.1080/16078454.2026.2762576 November 12, 2026.
Overview
This survey study explored the communication, information, and support needs of people living with multiple myeloma and identified helpful and unhelpful interactions with family, friends, and clinicians. The findings document important gaps and are intended to guide more patient-centered education, communication, and supportive care.
"Pentraxin-3 dynamics and treatment response in newly diagnosed multiple myeloma."
Source
Çiçek, A.N., Yılmaz, S., Özberk, Ö. et al. Pentraxin-3 dynamics and treatment response in newly diagnosed multiple myeloma. Int J Hematol (2026). https://doi.org/10.1007/s12185-026-04323-x November 12, 2026.
Overview
The study evaluated the association between dynamic changes in PTX3 levels and treatment response in newly diagnosed MM. This prospective single-center cohort study included 33 patients with newly diagnosed MM. These findings support further investigation of PTX3 dynamics in larger prospective cohorts.
"AI-Driven Analysis of Longitudinal MRI Marrow Patterns Predicts Survival in Multiple Myeloma Treatment."
Source
Chen, T., Zhou, C., Wang, Y., Hadjiiski, L. M., Dong, Q., & Wilms, M. (2026). AI- Driven Analysis of Longitudinal MRI Marrow Patterns Predicts Survival in Multiple Myeloma Treatment. Journal of Clinical Medicine, 15(22), 8906. https://doi.org/10.3390/jcm15228906 November 13, 2026.
Overview
This preliminary study evaluated the prognostic value of longitudinal changes in vertebral magnetic resonance imaging (MRI) patterns using a two-stage machine learning (2S-ML) framework. These preliminary findings suggest that AI-driven analysis of longitudinal vertebral MRI patterns may provide prognostic value for survival risk stratification in MM.
"Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations."
Source
Miyama, T., & Mihara, K. (2026). Insights into Multiple Myeloma: Immune Microenvironment, Disease Mechanisms, and Therapeutic Innovations. International Journal of Molecular Sciences, 27(22), 10183. https://doi.org/10.3390/ijms272210183 November 13, 2026.
Overview
This review synthesizes evidence on how immune dysfunction and spatially heterogeneous bone-marrow microenvironments shape progression from precursor disease, treatment resistance, and immune escape in multiple myeloma. It uses these mechanisms to frame priorities for rational development of next-generation immunotherapies.
"Impact of residual clonal plasma cell proliferation rate after autologous stem cell transplant on outcomes in multiple myeloma."
Source
Hellou, T., Packard, D.G., Steinhardt, M.J. et al. Impact of residual clonal plasma cell proliferation rate after autologous stem cell transplant on outcomes in multiple myeloma. Blood Cancer J. 16, 202 (2026). https://doi.org/10.1038/s41408-026-01676-8 November 13, 2026.
Overview
Given the distinct response kinetics of t(11;14) myeloma, in which residual disease may persist despite favorable outcomes, researchers explored whether post-ASCT S-phase could further discriminate prognosis within this subgroup. In conclusion, post-ASCT clonal plasma cell S-phase ≥2% independently identifies patients with MM at high risk for progression and death, while longitudinal changes in S-phase further characterize evolving disease biology.
"Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index."
Source
Saurabh Zanwar et al. Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index. J Clin Oncol 0, JCO-26-01039 DOI:10.1200/JCO-26-01039 November 13, 2026.
Overview
Researchers developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein-coupled receptor class 5 member D-directed TCEs. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7).
"Agent Orange Exposure Does Not Modify the Rate of Developing Certain Service-Connected Cancers in U.S. Veterans with Monoclonal Gammopathy of Undetermined Significance."
Source
Helen Ma, Lu He, Jia Y Wan, Wendy Cozen, Pankaj Gupta, Agent Orange Exposure Does Not Modify the Rate of Developing Certain Service-Connected Cancers in U.S. Veterans with Monoclonal Gammopathy of Undetermined Significance, Military Medicine, 2026;, usag515, https://doi.org/10.1093/milmed/usag515 November 13, 2026.
Overview
This retrospective Veterans Health Administration cohort study examined whether prior Agent Orange exposure altered the rate of subsequent service-connected cancers among patients with monoclonal gammopathy of undetermined significance. Agent Orange exposure was not associated with higher overall or cancer-specific rates during a median 5.2 years of follow-up.
"Metabolic targeting of multiple myeloma using the Warburg Trap."
Source
Hildenbrand, N., Tripel, E., Melnik, S. et al. Metabolic targeting of multiple myeloma using the Warburg Trap. Cancer Cell Int 26, 361 (2026). https://doi.org/10.1186/s12935-026-04504-y November 13, 2026.
Overview
This preclinical study tested the Warburg Trap strategy, which combines mitochondrial complex I inhibition with proton ionophores to disrupt pH and energy homeostasis in multiple myeloma cells. It evaluated cytotoxicity, drug synergy, and metabolic correlates to identify conditions and biomarkers associated with treatment sensitivity.
"Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey."
Source
Rahul Banerjee, Jay Hydren, Jorge Arturo Hurtado Martínez, Mason Barnes, Patricia Alejandra Flores Pérez, Jennifer M Ahlstrom, Kara I Cicero, Gurbakhash Kaur, Parisa Taravati, Andrew J Cowan, Ocular comorbidities are common in multiple myeloma: results of a large cross-sectional survey, The Oncologist, 2026;, oyag458, https://doi.org/10.1093/oncolo/oyag458 November 14, 2026.
Overview
This international survey quantified ocular comorbidities in people with multiple myeloma and examined treatment-related risk factors and eye-care counseling. Cataracts and dry eye were common, and higher weekly dexamethasone exposure was associated with earlier predicted cataract development.
"One clone, one mass: The rise of mass spectrometry in the diagnosis and monitoring of monoclonal gammopathies."
Source
Gema García de la Rosa, Silvia de las Heras Flórez, Cristina Agulló, Noemí Puig, One clone, one mass: The rise of mass spectrometry in the diagnosis and monitoring of monoclonal gammopathies, Clinica Chimica Acta, Volume 595, 2027, 122972, ISSN 0009-8981, https://doi.org/10.1016/j.cca.2026.122972. November 14, 2026.
Overview
This review evaluates mass spectrometry as a more sensitive method for diagnosing and monitoring monoclonal gammopathies than conventional electrophoresis and immunofixation. It summarizes prognostic evidence, its complementary role with marrow MRD testing, and the standardization, access, and implementation barriers that remain.
"Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the addition of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (Alliance A061402)."
Source
Sborov, D.W., Mahindra, A.K., Suman, V.J. et al. Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402). Blood Cancer J. 16, 203 (2026). https://doi.org/10.1038/s41408-026-01674-w November 16, 2026.
Overview
This phase 3 trial report describes the design and clinical course of patients with solitary plasmacytoma of bone treated with radiation and zoledronic acid, with or without oral lenalidomide, ixazomib, and dexamethasone. Its purpose was to explore whether adjuvant systemic therapy could delay progression to multiple myeloma, while highlighting the need for larger multicenter confirmation.
"Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody."
Source
Muhamed Baljevic, Peter Voorhees, Cesar Rodriguez, Anita D'Souza, Alfred Chung, Eben Isaac Lichtman, Hana Safah, Katja C Weisel, Ravi Vij, Hira Mian, Hila Magen, Emma Searle, John T. Mckay, Neha S. Korde, Saurabh Chhabra, Anders Svensson, Rajvineeth Kumar Pothacamury, Chetasi Talati, Carli Allendorf, Claudie Hecquet, Valerie Robinson, Aarif Ahsan, Shaji K. Kumar; Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody. Blood 2026; blood.2026034590. doi: https://doi.org/10.1182/blood.2026034590 November 16, 2026.
Overview
The report describes long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.
"A real-time text-based assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study."
Source
Tellez V, Bommaraju A, Cheung J, Swift R, Moore J, Sayad P, et al. A real-time textbased assessment tool for monitoring symptoms and quality of life for multiple myeloma patients: A feasibility study. Br J Haematol. 2026; 00: 1-11. https://doi.org/10.1111/bjh.70940 November 16, 2026.
Overview
This feasibility study evaluated an SMS-based platform for frequent remote monitoring of symptoms and quality of life in patients with multiple myeloma. High completion rates and rapid clinician responses to actionable alerts support its potential for low-burden therapeutic monitoring between visits.
"Macrophage Immunometabolic Reprogramming in Multiple Myeloma: Linking Spatial Niches to Therapy Resistance."
Source
Wu, B., Zhou, W., & Wu, W. (2026). Macrophage Immunometabolic Reprogramming in Multiple Myeloma: Linking Spatial Niches to Therapy Resistance. Immunological Investigations, 1-39. https://doi.org/10.1080/08820139.2026.2757126 November 16, 2026.
Overview
This review examines how spatial niches and metabolic reprogramming shape macrophage function and contribute to therapy resistance. Most supporting evidence comes from preclinical and in vitro studies, and these strategies require clinical validation.
"Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial."
Source
Giuseppe Bertuglia, Mattia D'Agostino, Delia Rota-Scalabrini, Angelo Belotti, Laura Paris, Micol Quaresima, Sonia Morè, Stelvio Ballanti, Sara Aquino, Paolo De Fabritiis, Francesca Fioritoni, Michele Cea, Nicola Giuliani, Francesca Patriarca, Stefania Oliva, Massimo Gentile, Francesca Fazio, Renato Zambello, Sara Bringhen, Paolo Corradini, Benedetto Bruno, Elena Zamagni, Mario Boccadoro, Pellegrino Musto, Francesca Gay; Carfilzomib-based strategies in transplant-eligible multiple myeloma: long-term follow-up of the phase 2 FORTE trial. Blood 2026; blood.2026035635. doi: https://doi.org/10.1182/blood.2026035635 November 16, 2026.
Overview
This long-term follow-up of the phase 2 FORTE trial compared carfilzomib-based induction and consolidation strategies and evaluated maintenance approaches in transplant-eligible newly diagnosed multiple myeloma. The updated results support durable benefit with KRd followed by autologous transplantation and with carfilzomib-containing maintenance.
"EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA-Approved Bispecific Antibodies."
Source
Shah PD, Yeremian S, Forte E, et al. EXPRESS: A Meta-analysis Reporting the Most Common Infectious Complications in Relapsed/Refractory Multiple Myeloma Patients Treated with FDA Approved Bispecific Antibodies. Journal of Investigative Medicine. 2026;0(ja). doi:10.1177/10815589261507073 November 17, 2026.
Overview
This meta-analysis estimated the frequency and severity of infections reported with teclistamab, talquetamab, and elranatamab in relapsed or refractory multiple myeloma. Infections were common across the eight included studies, although substantial heterogeneity limits direct comparisons and underscores the need for standardized definitions and follow-up.
"Treatment journey and outcomes of patients with RRMM after quadruple-class exposure: a critical unmet need."
Source
Doris K. Hansen, Lin Wang, Fangyi Gu, Teofilia Acheampong, Meghan Podolsky, Jaclyn Davis, Krina K. Patel; Treatment journey and outcomes of patients with RRMM after quadruple-class exposure: a critical unmet need. Blood Adv 2026; bloodadvances.2026021159. doi: https://doi.org/10.1182/bloodadvances.2026021159 November 17, 2026.
Overview
This real-world study traced treatment pathways and outcomes after quadruple-class exposure in relapsed or refractory multiple myeloma using electronic health record data. Short event-free survival and deaths before subsequent therapy demonstrate a major unmet need for earlier access to effective novel treatments.
"Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial."
Source
Puliafito B, Graham C, Raje N et al. Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial The Lancet, 2026; 0 November 17, 2026.
Overview
The study aimed to establish the safety, tolerability, preliminary efficacy, and recommended phase 2 dose of autologous TriPRIL CAR T cells. In this first-in-human, open-label, dose-escalation and dose-expansion, phase 1 study, researchers evaluated TriPRIL in patients with relapsed or refractory multiple myeloma at Massachusetts General Hospital (Boston, MA, USA). The study findings support further development of this dual-targeted, natural ligand-based CAR T-cell approach.
"Image quality and dose performance of photon-counting CT in multiple myeloma: a comparative clinical study."
Source
Woeltjen, M.M., Salim, S.A., Schoenbeck, D. et al. Image quality and dose performance of photon-counting CT in multiple myeloma: a comparative clinical study. J Cancer Res Clin Oncol 152, 230 (2026). https://doi.org/10.1007/s00432-026-06655-x November 17, 2026
Overview
To compare image quality and radiation-dose indices between photon-counting computed tomography (PCCT) and conventional energy-integrating detector CT (EID-CT) examinations in patients with multiple myeloma. This retrospective intraindividual study included 47 patients with non-contrast whole-body PCCT examinations (NAEOTOM Alpha, Siemens Healthineers) and prior EID-CT examinations (SOMATOM Sensation 64, Siemens Healthineers). In non-contrast whole-body imaging of patients with multiple myeloma, the evaluated PCCT system provided superior image quality and significantly lower radiation-dose indices than the historical EID-CT system.
"Quantification of lenalidomide and pomalidomide enantiomers in multiple myeloma patients: An exploratory study."
Source
Vardhan, G., Kumar, V., Kumar, A., Nath, U. K., Handu, S., & Dhamija, P. (2026). Quantification of lenalidomide and pomalidomide enantiomers in multiple myeloma patients: An exploratory study. Indian Journal of Pharmacology, 58(6), 784-790. https://doi.org/10.4103/ijp.ijp_219_26 Nov-Dec 2026.
Overview
This study developed and validated a novel chiral stationary phase high-performance liquid chromatography (CSP-HPLC) method to quantify LND and PMD enantiomers in human plasma. These findings provide a basis for developing enantiomeric compounds of LND and PMD, which could lead to more effective and safer treatments for MM.
"Bringing Treatment Home: Daratumumab Administration by Danish Community Nurses in Multiple Myeloma-A Mixed-Method Study."
Source
Jannie, K., Tine, R., Brochstedt, D. K., & Thomas, L. (2026). Bringing Treatment Home: Daratumumab Administration by Danish Community Nurses in Multiple Myeloma- A Mixed-Method Study. Home Healthcare Now, 44(6), 355-366. https://doi.org/10.1097/NHH.0000000000001476 Nov-Dec 2026.
Overview
This prospective mixed-methods study assessed the feasibility, safety, patient experience, and quality-of-life implications of community nurses administering subcutaneous daratumumab at home or in local clinics. Most participants favored community delivery, but successful implementation depended on patient selection, training, communication, and reliable care coordination.
"Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab."
Source
Lancman G, Sastow D, Aslanova M, Moshier E, Cho HJ, Jagannath S, Parekh S, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Thibaud S, Chari A. Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab. Haematologica 2026; 111(11):3712-3720; https://doi.org/10.3324/haematol.2025.289215. November 2026.
Overview
This retrospective study examined whether intravenous immunoglobulin reduced infections among patients with multiple myeloma receiving daratumumab and experiencing hypogammaglobulinemia. During IVIG use, all-grade and grade 3-4 infections were lower, suggesting benefit for selected patients with recurrent infections.




